Dados do Trabalho

Título

HYPOGLYCEMIA IN PATIENTS WITH LAMA2-CMD

Introdução

Hypoglycemia has been reported in LAMA2-CMD patients, but the frequency, risk factors, and correlation to genotype/phenotype have not been systematically assessed to date.

Objetivo

The aim of this study was to identify the frequency of hypoglycemia in a large cohort of LAMA2-CMD patients and to correlate it with findings of phenotypes and genotypes that enhance possible risk factors and triggers.

Métodos

A retrospective cohort study was performed on 48 patients with LAMA2-CMD. Patients were divided into 2 groups: a hypoglycemic group, with at least 1 episode of hypoglycemia, and a nonhypoglycemic group. The groups were compared according to gait function, epilepsy, intellectual disability, constipation, gastroesophageal reflux, gastrostomy, weight percentile, scoliosis, the use of a ventilator device, the use of a feeding device, neuromuscular disease swallowing status scale, and type of mutation.

Resultados

Fifteen patients (31.2%) presented with at least 1 episode of symptomatic hypoglycemia and 8 (16.6% of the cohort) had 2 or more episodes. All patients who had hypoglycemia were in the nonambulant group. A correlation was observed between gait, the use of ventilator and feeding devices, and swallow function with hypoglycemia. Patients with extreme low weight were 5 times more likely to have recurrent episodes of hypoglycemia. The presence of at least 1 missense variant appears to be associated with a lower risk of hypoglycemia.

Conclusões

Patients with LAMA2-CMD are at risk of hypoglycemia. The risk is more relevant in patients with severe phenotype and patients with loss of function variants. For patients with extremely low weight, the risk is higher. Blood glucose should be actively measured in patients who are fasting or have infections, and health care providers should be prepared to identify and treat these patients.

Palavras chave

LAMA2-CMD, hypoglycemia, genotype-phenotype, metabolism, weight

Referências (se houver)

1- Darin N.; Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscular Disorders. 2000. 1:1
2- Graziano A, Bianco F, D’Amico A, et al. Prevalence of congenital muscular dystrophy in Italy: a population study. Neurology. 2015;84:904–11
3- Reed, U.C. 2009. Congenital Muscular Dystrophy. Part1: a review of phenotypical and diagnostic aspects. Arq Neuropsquiatr. 2009; 67(1):144-168. https://doi.org/10.1590/S0004-282X2009000100038
4- Quijano-Roy. LAMA2-Related Muscular Dystrophy, 2012. GeneReviews.
5- Oliveira J; Parente Freixo J; Santos M; Coelho T. LAMA2 gene analysis in a cohort of 26 congenital muscular dystrophy patients. Clin Genet.2008 Dec;74(6):502-12.
6- Oliveira J; Parente Freixo J; Santos M; Coelho T. LAMA2 Muscular Dystrophy. 2020. Genereviews
7- Hypoglycemia in a child with congenital muscular dystrophy. Shu S, Cruse RP, Redmond GP. Brain Dev. 1989;11(1):62-5. doi: 10.1016/s0387-7604(89)80011-7.
8- Bruce AK, Jacobsen E, Dossing H, et al. Hypoglycaemia in spinal muscular atrophy. Lancet. 1995;346:609–10. doi: 10.1016/s0140-6736(95)91439-0.
9- Hayes, L.H., Yun, P., Mohassel, P. et al. Hypoglycemia in patients with congenital muscle disease. BMC Pediatr 20, 57 (2020). https://doi.org/10.1186/s12887-020-1909-5
10- Wada A, Kawakami M, Liu M, Otaka E, Nishimura A, Liu F, Otsuka T. Development of a new scale for dysphagia in patients with progressive neuromuscular diseases: the Neuromuscular Disease Swallowing Status Scale (NdSSS). J Neurol. 2015 Oct;262(10):2225-31. doi: 10.1007/s00415-015-7836-y. Epub 2015 Jul 4. PMID: 26142025.
11- Sunehag AL, Treuth MS, Toffolo G, et al. Glucose production, gluconeogenesis, and insulin sensitivity in children and adolescents: an evaluation of their reproducibility. Pediatr Res. 2001;50:115–23. doi: 10.1203/00006450-200107000-00021.
12- Fontes-Oliveira, C., Steinz, M., Schneiderat, P. et al. Bioenergetic Impairment in Congenital Muscular Dystrophy Type 1A and Leigh Syndrome Muscle Cells. Sci Rep 7, 45272 (2017). https://doi.org/10.1038/srep45272
13- Koopman, R.; Hai Ly, C.; Ryall, JG. A metabolic link to skeletal muscle wasting and regeneration. Front. Physiol., 5, 32, 1-11, 2014.
14- Katsetos, CD.; Koutzaki, SMS.; Melvin, JJ. Semin Pediatr Neuro. 2013 Sep;20(3):202-15. doi: 10.1016/j.spen.2013.10.010
15- Oliveira, BM; Matsumura CY; Fontes-Oliveira C. et al. Quantitative proteomic analysus reveals meatbolic alterations, calcium dysregulation, and increased expression. Of extracelular matrix proteins in laminin alpha2 Chain-deficient muscle. Molecular & Cellular Proteomics, 13.11, 3001-3013 (2014)

Fonte de Fomento (se houver)

Declaração de conflito de interesses de TODOS os autores

Não há conflito de interesse de NENHUM dos autores

Área

Doenças neuromusculares